Optimistic Buy Rating for Vera Therapeutics Amid Strategic Advancements and Financial Projections

Tip Ranks
2025.12.04 23:35
portai
I'm PortAI, I can summarize articles.

Analyst Ritu Baral of TD Cowen maintains a Buy rating on Vera Therapeutics, raising the price target to $73 due to optimistic financial projections and strategic advancements. Vera Therapeutics has increased its estimated pricing for atacicept, boosting projected US sales to $1.64 billion by 2033. The company is advancing its clinical pipeline and exploring new dosing regimens, enhancing market potential. J.P. Morgan also maintains a Buy rating with a $99 price target.

Analyst Ritu Baral of TD Cowen maintained a Buy rating on Vera Therapeutics, boosting the price target to $73.00.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Ritu Baral has given her Buy rating due to a combination of factors including an optimistic outlook on Vera Therapeutics’ financial projections and strategic developments. The company has increased its estimated gross annual pricing for atacicept in IgAN to $350,000, which is significantly higher than previous estimates, driven by new competitor pricing. This adjustment has led to an increase in the projected peak sales in the US to $1.64 billion by 2033, prompting an upward revision of the price target to $73.
Furthermore, Vera Therapeutics is making promising advancements in its clinical pipeline, particularly with the ongoing Phase 2b PIONEER basket study. This study is expanding into new cohorts and indications, potentially broadening the market for atacicept. The company is also exploring a monthly dosing regimen, which could enhance patient compliance and marketability. These strategic initiatives, along with the potential for a mid-year 2026 PDUFA decision, contribute to the positive outlook and the Buy rating.

In another report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $99.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer